Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay later under a partnership

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks like we'll have the next generation of these breakthrough weight loss and diabetes medicines on shelves by early next year.

“While the weight loss results were impressive across the group, the cost and side effects remain important barriers for long-term use. Two of them discontinued after a few months due to the high cost. One of these patients also experienced severe vomitting and couldn’t tolerate the drug, leading to early discontinuation,” says Dr Misra.

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24.

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed semaglutide had a 50% higher risk of being diagnosed with a hair-loss condition compared to those prescribed Contrave. That risk was twice as high for women as for men.

Novo Nordisk said it had agreed to license a potential rival to its weight-loss drug Ozempic from a Chinese company. The Danish pharma company said it would pay $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the rights to UBT251,

(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United Laboratories International's weight-loss drug candidate in a deal worth up to $2 billion.